Page 1

SILENCE THERAPEUTICS NEWS RELEASE Silence Therapeutics Reports Half - Year 2021 Results 8/12/2021 • Silence Therapeutics Reports Half - Year 2021 Results Full enrollment achieved for four cohorts of the APOLLO study of SLN360 in healthy individuals living with high levels of lipoprotein ( a ) August 12 , 2021 • Silence to host R & D Day in New York City on October 21 , 2021 LONDON , Silence Therapeutics plc , AIM : SLN and Nasdaq : SLN ( " Silence " or " the Company " ) , a leader in the discovery , development and delivery of novel short interfering ribonucleic acid ( siRNA ) therapeutics for the treatment of diseases with significant unmet medical need , today announced results for its half - year ended June 30 , 2021 . Mark Rothera , President and CEO of Silence Therapeutics , commented : " The first half of 2021 was marked by strong execution , highlighted by the first clinical data from our proprietary mRNAI GOLD ™ platform that successfully translated results from pre - clinical models into humans . In addition to achieving positive clinical data from our platform , we started dosing patients in two wholly owned programs and added two new targets to our partnered pipeline . The progress we made across both our proprietary and partnered pipelines underscores our firm commitment to maximize the substantial opportunity of our mRNAi GOLD TM platform and enable 2-3 INDs per year beginning in 2023. " " Looking ahead , we have now fully enrolled four cohorts of the APOLLO study of SLN360 in healthy individuals living with high levels of Lp ( a ) and we anticipate topline data in the first quarter of 2022. We look forward to 1